Strategic Partnerships Henlius has active and growing collaborations with global players (Sandoz, Intas, Lotuspharm) and seeks expanded regional licensing opportunities, indicating strong potential to pitch additional co-development, co-marketing, or regional distribution deals to accelerate market access.

Global Expansion With a pipeline centered on oncology and plans for expansions into autoimmune and inflammatory diseases, there are sales opportunities to position Henlius as a preferred partner for regional biopharma players seeking diversification and access to a diversified oncology portfolio.

Orphan and ADC Focus Achievements such as Orphan Drug Designation for HLX43 and the development of HER2 biparatopic ADCs highlight niche capabilities. This can be leveraged to target specialty oncology clinics and government programs seeking innovative orphan or ADC therapies.

Global Commercial Readiness Active participation in major conferences (AACR, JP Morgan Healthcare Conference) and a sizeable revenue scale suggest Henlius has a credible commercial footprint. This makes them a viable partner for contract manufacturing, global supply agreements, and market access ventures.

Regional Licensing Potential Existing exclusive rights and licensing deals in Europe, India, and South Korea indicate a readiness to expand partnerships by leveraging Henlius’ multi-region strategy to accelerate launches in additional markets and diversify risk for distributors and CROs.